CORTHIGH SIGNALFINANCIAL10-K

CORT experienced a dramatic 67% decline in operating income despite 13% revenue growth, driven by a massive 60% increase in SG&A expenses and an unprecedented 1,000% surge in share buybacks.

The company's profitability has deteriorated significantly as expenses ballooned far beyond revenue growth, suggesting either major inefficiencies or substantial strategic investments that haven't yet translated to bottom-line performance. The massive increase in share buybacks to $173M signals management's confidence in the business despite operational challenges, but also raises questions about capital allocation priorities when operating performance is declining.

Comparing 2026-02-24 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

CORT delivered mixed results with revenue growing a solid 13% to $761M, but this was overshadowed by operating income plummeting 67% due to SG&A expenses surging 60% to $449M. The company dramatically increased share buybacks by over 1,000% to $173M while operating cash flow declined 28%, and liabilities increased 17%, painting a picture of a company struggling with cost control despite strong top-line growth. The financial profile suggests significant operational challenges that investors should monitor closely despite management's apparent confidence reflected in the aggressive share repurchase program.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+1003.9%
$15.7M$172.9M

Share repurchases increased 1003.9% — management returning capital, signals confidence in intrinsic value.

Capital Expenditure
Cash Flow
-90.3%
$2.2M$211K

Capex reduced 90.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
-67.3%
$137.0M$44.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

SG&A Expense
P&L
+60.1%
$280.3M$448.7M

SG&A up 60.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Net Income
P&L
-29.4%
$141.2M$99.7M

Net income declined 29.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-28.3%
$198.1M$142.0M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Current Liabilities
Balance Sheet
+18%
$140.8M$166.1M

Current liabilities rose 18% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+17.3%
$161.0M$188.8M

Liabilities increased 17.3% — monitor debt-to-equity ratio and interest coverage.

Revenue
P&L
+12.8%
$675.0M$761.4M

Revenue growing 12.8% — solid top-line momentum, watch margins for quality of growth.

Accounts Receivable
Balance Sheet
+10.8%
$54.0M$59.8M

Receivables grew 10.8% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-26
ADDED
On February 17, 2026 there were 106,374,020 shares of common stock outstanding at a par value of $0.001 per share.
Our lead compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic and prostate cancers), ALS and MASH.
From 2017 until 2025, we used an exclusive specialty pharmacy vendor, Optime Care, Inc.
( Optime ) and a specialty distributor to distribute our Products and provide logistical support to physicians and patients.
In June 2025, we notified Optime that it would cease to be our exclusive specialty pharmacy and in October 2025, we delivered a notice of termination of our agreement with them, effective January 8, 2026.
+7 more — sign up free →
REMOVED
On February 18, 2025 there were 105,503,432 shares of common stock outstanding at a par value of $0.001 per share.
On December 30, 2024, we submitted to the United States Food and Drug Administration ( FDA ) a New Drug Application ( NDA ) for a proprietary cortisol modulator we have developed, relacorilant, that, like Korlym, modulates the effects of cortisol by binding at the GR, but has no affinity for the PR and so does not cause PR-related side effects.
Our lead compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders hypercortisolism, advanced ovarian cancer, prostate cancer, ALS and MASH.
We use a specialty pharmacy and a specialty distributor to distribute our Products and provide logistical support to physicians and patients.
CATALYST s primary endpoint was the difference in HbA1c in patients who received Korlym compared to patients who received placebo.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →